Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq on primary human kidney epithelial cells with oleate treatment and PLIN2 knockdown

ABSTRACT: RNA-seq on primary human kidney epithelial cells with oleate treatment and PLIN2 knockdown

PROVIDER: PRJNA849157 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19648657_1.fastq.gz	Fastqsanger.gz
	SRR19648657_2.fastq.gz	Fastqsanger.gz
	SRR19648658_1.fastq.gz	Fastqsanger.gz
	SRR19648658_2.fastq.gz	Fastqsanger.gz
	SRR19648659_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

RNA-seq on primary human kidney epithelial cells with oleate treatment and PLIN2 knockdown

Project description:Here we investigated the transcriptomic changes induced by oleic acid treatment on human Primary Renal Proximal Tubule Epithelial Cells (RPTECs) with RNA-seq. We also profiled cells with oleic acid treatment after PLIN2 gene knockdown with siRNA treatment.

2022-10-01 | GSE206084 | GEO

RNA-seq on primary human kidney epithelial cells with PPFIBP1 or PLEKHA1 knockdown

Project description:RNA-seq on primary human kidney epithelial cells with PPFIBP1 or PLEKHA1 knockdown

| PRJNA1004535 | ENA

RNA-seq of human HepG2 cells treated with sodium oleate, 17β-estradiol and ER-alpha siRNA

Project description:HepG2 cells are only treated with 60 μg/ml sodium oleate as group 1, and treated with 60 μg/ml sodium oleate and 50 ng/ml E2 as group 2, and treated with 60 μg/ml sodium oleate, 50 ng/ml E2 and ER-alpha as group 3. All the treatment last for 48 hours and each group have two replications.

2019-10-05 | E-MTAB-7318 | biostudies-arrayexpress

GENE TARGETS OF PALMITATE, OLEATE AND THEIR MIXTURE IN CULTURED LHCN-M2 MYOTUBES

Project description:A global transcriptomic study enables investigating human skeletal muscle gene targets of palmitate versus oleate and the capacity of oleate to alter palmitate-effects.

2015-12-01 | GSE53116 | GEO

Oleate-degrading enrichment cultures

Project description:Methanogenic and non-methanogenic oleate-degrading enrichment cultures

| PRJEB25834 | ENA

Proteomics of Escherichia coli with sodium oleate and/or gentamicin treatment

Project description:Sodium oleate alters the proteomics of Escherichia coli to decrease the sensitivity to gentamicin

2025-07-17 | PXD066294 |

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate.

Project description:Potent chemotherapeutic agents are required to counteract the aggressive behavior of cancer cells and patients often experience severe side effects, due to tissue toxicity. This study addresses if a better balance between efficacy and toxicity can be attained using the tumoricidal complex alpha1-oleate, formed by a synthetic, alpha-helical peptide comprising the N-terminal 39 amino acids of alpha-lactalbumin and the fatty acid oleic acid. Bladder cancer was established, by intra-vesical instillation of MB49 cells on day 0 and the treatment group received five instillations of alpha1-oleate (1.7-17mM) on days 3-11. A dose-dependent reduction in tumor size, bladder size and bladder weight was recorded in the alpha1-oleate treated group, compared to sham-treated mice. Tumor markers Ki-67, Cyclin D1 and VEGF were inhibited in a dose-dependent manner, as was the expression of cancer-related genes. Remarkably, toxicity for healthy tissue was not detected in alpha1-oleate-treated, tumor bearing mice or in healthy mice or rabbits, challenged with increasing doses of the active complex. The results define a dose-dependent therapeutic effect of alpha1-oleate in a murine bladder cancer model.

2020-04-09 | GSE148308 | GEO

ChIP-CHIP data for oleate-specific transcriptional regulatory network analysis

Project description:The goal of the study was to determine the direct targets of four oleate-responsive transcription factors (Oaf1p, Pip2p, Oaf3p, Adr1p) in the presence and absence of the fatty acid oleate. This data is part of a larger study outlined below: A novel network topology-based clustering approach was used to characterize a dynamic transcriptional regulatory network responsive to the fatty acid oleate. Condition-specific large-scale chromatin localization data were generated for four fatty-acid related regulators, and used to construct physical interaction networks. Data integration and simple statistical analysis of dynamic network architecture led to the identification of a regulatory role for a previously uncharacterized protein, and unique mechanism for coordination and regulation of multiple biological responses through the formation of related parallel combinatorial control motifs. Temporal coordination and specificity are achieved through the ability of a regulator (Oaf1p) to have multiple context-specific activities under the same condition. The analysis suggests that active paths for a transcriptional response can be highly interconnected in parallel and involve multiple functions for individual regulators through combinatorial control. Keywords: ChIP-chip, growth condition

2007-04-19 | GSE5863 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, long-term effects

Project description:Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of non-muscle invasive bladder cancer. This study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least four weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer.

2023-02-25 | GSE209881 | GEO

Expression data from mice bladder with MB49-induced cancer treated with alpha1-oleate alone or in combination Epirubicin or Mitomycin C, short-term effects

2023-02-25 | GSE209882 | GEO